Wilfried Bakker earned his Ph.D. in Bioprocess Engineering from Wageningen University. Subsequently, he became a staff-member at Utrecht University, Faculty of Veterinary Medicine. Next, before joining Intravacc, he held R&D and management positions in several Dutch biotechnology companies (Diosynth, Crucell, Sanquin) to manufacture products ranging from classical biopharmaceuticals to adenoviral vectors for human gene therapy.
Currently, Wilfried has over 12 years of experience in vaccinology. He is program manager at Intravacc and leads the development, application and valorization of innovative viral vaccine platform technologies. As an example, one of the major projects is the successful fast-track development, optimization and technology transfer of a new candidate Sabin-IPV (sIPV) in collaboration with the World Health Organization (WHO). Recently, sIPV clinical studies in adults and infants were successfully completed, and currently local phase III clinical studies are ongoing. The sIPV product launch, by our technology transfer partners, is now anticipated in the coming 1 – 2 years. Dr. Bakker authored over 40 peer-reviewed scientific publications, and served several times as a temporary advisor for WHO.